Artemis Medicare Q4 FY26 revenue rises 16.4% to Rs. 27,923 lakh, net profit jumps 32.1%

The hospital chain reported strong growth driven by its Gurugram facility, international patient inflow, and operational efficiencies

Lupin Q4 FY26 PBT jumps 115% to Rs 19,280 million

U.S. business drives strong growth as Lupin reports 57% rise in Q4 U.S. sales and 43% increase in gross profit

Ajanta Pharma Q4 FY26 revenue surges 21% to Rs. 1,422 Crore; PAT climbs 18%

FY26 revenue rises 17% to Rs. 5,453 crore as US generics business jumps 49% and adjusted EBITDA margin improves to 26% for the quarter

Dr Lal PathLabs posts strong Q4 FY26 results with 16.6% revenue growth & PAT at Rs. 132 Cr

The company posted revenue of Rs. 703 crore in Q4 FY26

From losses to lift-off: Astec gains ground in Q4 FY26

The company reported consolidated total income of Rs. 161.3 crore in Q4 FY26, a strong jump from Rs. 120.3 crore in the same period last year

Orchid Pharma submits Q4 FY26 SEBI compliance certificate to NSE, BSE

Routine regulatory filing confirms completion of demat and share transfer compliances for March quarter

Dabur reports steady domestic growth amid global headwinds in Q4 FY26

The India FMCG business showed a sequential recovery and is expected to post high-single digit growth

Wanbury FY26 PAT surges 117% to Rs. 66.1 crore

Glenmark posts strong FY26 results with 27.5% revenue jump

Alkem Labs posts highest-ever EBITDA in FY26; Q4 revenue rises 14.6%

Strong domestic and international growth, improving product mix, and operational efficiencies drive margin expansion despite exceptional charges impacting quarterly profit